Clinical Trial Update: JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia [NA]

View source ↗

Summary

A clinical trial update indicates that JY231 injections are being studied for relapsed/refractory B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lym…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia
• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• JY231

Snippet

Sponsor: Shenzhen Genocury Biotech Co., Ltd. | Conditions: B Acute Lymphoblastic Leukemia, B-Non Hodgkin Lymphoma | NA | Status: RECRUITING